IBMX

IBMX
IBMX
Skeletal formula of IBMX
Space-filling model of the IBMX model
이름
IUPAC 이름
1-메틸-3-(2-메틸프로필)-7H-푸린-2,6-디오네
기타 이름
3-이소부틸-1-메틸크산틴
식별자
3D 모델(JSmol)
체비
켐벨
켐스파이더
드러그뱅크
ECHA InfoCard 100.044.767 Edit this at Wikidata
케그
펍켐 CID
유니
  • InChi=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12) checkY
    키: APIXJSLKIYYUKG-UHFFFAOYSA-N checkY
  • InChi=1/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(14)16/h5-6H,4H2,1-3H3,(H,11,12)
    키: APIXJSLKIYUKG-UHFFFAOYAL
  • CC(C)Cn1c2c(c(=O)n(c1=O)C)[nH]cn2
특성.
C10H14N4O2
어금질량 222.3 g/192
외관 화이트솔리드
녹는점 199~201°C(390~394°F, 472~474K)
용해성 에탄올, DMSO, 메탄올에 용해성
달리 명시된 경우를 제외하고, 표준 상태(25°C [77°F], 100 kPa)의 재료에 대한 데이터가 제공된다.
check 이버라이시checkY☒N(?)
Infobox 참조 자료

IBMX(3-isobutyl-1-methylxantine)는 다른 메틸화 크산틴 유도체와 마찬가지로 모두 a:

  1. 세포내 cAMP를 높이고 PKA를 활성화하며 TNFα와[2][3] 백혈구[4] 합성을 억제하고 염증과 선천적 면역력을 [4]감소시키는 경쟁적 비선택적 인산염 억제제[1]
  2. 비선택성 아데노신 수용체 [5]길항제

인산염 테라제 억제제로서 IBMX는 IC50 = 2–50 μM을[6] 가지고 있으며, PDE8이나 PDE9를 억제하지 않는다.[7]

참조

  1. ^ Essayan, DM (November 2001). "Cyclic Nucleotide Phosphodiesterases". The Journal of Allergy and Clinical Immunology. 108 (5): 671–80. doi:10.1067/mai.2001.119555. PMID 11692087.
  2. ^ Deree, J; Martins, JO; Melbostad, H; Loomis, WH; Coimbra, R (June 2008). "Insights into the Regulation of TNF-α Production in Human Mononuclear Cells: The Effects of Non-Specific Phosphodiesterase Inhibition". Clinics (Sao Paulo). 63 (3): 321–8. doi:10.1590/S1807-59322008000300006. PMC 2664230. PMID 18568240.
  3. ^ Marques, LJ; Zheng, L; Poulakis, N; Guzman, J; Costabel, U (February 1999). "Pentoxifylline Inhibits TNF-α Production from Human Alveolar Macrophages". American Journal of Respiratory and Critical Care Medicine. 159 (2): 508–11. doi:10.1164/ajrccm.159.2.9804085. PMID 9927365.
  4. ^ a b Peters-Golden, M; Canetti, C; Mancuso, P; Coffey, MJ (15 January 2005). "Leukotrienes: Underappreciated Mediators of Innate Immune Responses" (PDF). Journal of Immunology. 174 (2): 589–94. doi:10.4049/jimmunol.174.2.589. PMID 15634873.
  5. ^ Daly, JW; Jacobson, KA; Ukena, D (1987). "Adenosine Receptors: Development of Selective Agonists and Antagonists". Progress in Clinical and Biological Research. 230: 41–63. PMID 3588607.
  6. ^ Beavo, JA; Rogers, NL; Crofford, OB; Hardman, JG; Sutherland, EW; Newman, EV (November 1970). "Effects of Xanthine Derivatives on Lipolysis and on Adenosine 3',5'-Monophosphate Phosphodiesterase Activity". Molecular Pharmacology. 6 (6): 597–603. PMID 4322367.
  7. ^ Soderling, SH; Beavo, JA (April 2000). "Regulation of cAMP and cGMP Signaling: New Phosphodiesterases and New Functions". Current Opinion in Cell Biology. 12 (2): 174–9. doi:10.1016/s0955-0674(99)00073-3. PMID 10712916.